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Abstract: Nonalcoholic liver disease (NAFLD) is manifested with a wide spectrum of clinical
symptoms and is closely associated with the metabolic syndrome, inflammation, and mitochondrial
dysfunction. Although the mechanism of mitochondrial dysfunction in NAFLD is still not fully
elucidated, multiple studies have demonstrated evidence of molecular, biochemical, and biophysical
mitochondrial abnormalities in NAFLD. Given the association between NAFLD and mitochondrial
dysfunction, the aim of this study is to analyze circulating levels of Krebs cycle intermediates in a
cohort of NAFLD-affected individuals and matching healthy controls and to correlate our findings
with the liver function metrics. Standard serum biochemistry and Krebs cycle intermediates were
analyzed in NAFLD (n = 22) and matched control (n = 67) cohorts. Circulating levels of isocitrate
and citrate were significantly (p < 0.05) elevated in the NAFLD cohort of patients. The area under
the curve (AUROC) for these two metabolites exhibited a moderate clinical utility. Correlations
between plasma Krebs cycle intermediates and standard clinical plasma metrics were explored by
Pearson’s correlation coefficient. The data obtained for plasma Krebs cycle intermediates suggest
pathophysiological insights that link mitochondrial dysfunction with NAFLD. Our findings reveal
that plasma isocitrate and citrate can discriminate between normal and NAFLD cohorts and can be
utilized as noninvasive markers of mitochondrial dysfunction in NAFLD. Future studies with large
populations at different NAFLD stages are warranted.
Keywords: plasma Krebs cycle intermediates; nonalcoholic fatty liver disease (NAFLD);
mitochondrial dysfunction
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the United States,
potentially leading to fibrosis, cirrhosis, and hepatocellular carcinoma progress [1–4]. NAFLD is
manifested with a wide spectrum of clinical symptoms while disease pathogenesis is described through
a “multiple-hit model.” The model takes into consideration multiple factors that may contribute to
the disease progress and staging [5]. Indeed, NAFLD is closely associated with metabolic syndrome,
inflammation, and mitochondrial dysfunction [4,6–8]. Although the mechanism of mitochondrial
dysfunction in NAFLD is still not fully elucidated, multiple studies have demonstrated evidence
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of molecular, biochemical, and biophysical mitochondrial abnormalities in NAFLD. Mitochondria
play a very significant role in hepatic cellular metabolism. Indeed, NAFLD-affected individuals
exhibit morphological changes in liver mitochondria and a decrease in ATP production [9]. Decreased
expression of mtDNA-encoded polypeptides and low activity of complexes I, III, and V were also found
in nonalcoholic steatohepatitis (NASH) patients [10]. Studies in animal models demonstrate oxidative
stress, decreased activity of OXPHOS proteins, high levels of circulating TNF-α, and accumulation
of hepatic cardiolipin and ubiquinone [9,11]. Regardless of the mechanism involved, these data
provide compelling evidence that mitochondrial dysfunction contributes to the NAFLD phenotype.
In the setting of impaired mitochondrial function, Krebs cycle involvement in NAFLD pathogenesis is
expected. The Krebs cycle is a central mitochondrial pathway that serves as a metabolic hub for aerobic
respiration, glycolysis, lipogenesis, gluconeogenesis, and amino acid synthesis. For every turn of the
cycle, there is a simultaneous reduction of NAD+ and ubiquinone. Subsequent oxidation of NADH
and FADH2, followed by ADP phosphorylation, leads to ATP synthesis. Disruption of the Krebs cycle
may lead to a wide range of metabolic disturbances and clinical symptoms. Given the association
between NAFLD and mitochondrial dysfunction, the aim of this study is to analyze circulating levels
of Krebs cycle intermediates in a cohort of NAFLD-affected individuals and matching healthy controls,
and correlate our findings to the liver function clinical metrics.
2. Experimental Section
2.1. Subjects
NAFLD (n = 22) and matched control cohorts (n = 67) included both genders in the age range
23–67 years old. The diagnosis of NAFLD was made on clinical and ultrasound evidence and
by excluding other causes of abnormal liver function tests. The sonographic findings have been
validated in the past [12]. Blood samples were drawn presumably after an overnight fast, although
later plasma glucose analysis revealed that not all subjects were compliant with the fasting protocol.
Informed consent was obtained from all subjects and the procedures were conducted in compliance
with the Institutional Review Board at Metro Health Medical Center. All plasma sample were
analyzed for liver transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase
(AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), bilirubin, albumin, creatinine, glucose,
HbA1C, triglycerides (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-C), and
inflammatory markers.
2.2. Sample Preparation for Krebs Cycle Intermediates
A total of 350 µL of plasma was spiked with 50 µL of a 0.2 mM mixture of tricarballylic
acid, 13C4-malate (Millipore Sigma, Burlington, MA, USA), d6-succinate (Millipore Sigma),
d6-α-ketoglutarate (Millipore Sigma), and 2 mM of 13C6-citrate (Millipore Sigma) followed by the
addition of 25 µL of 13C-4-fumarate (Millipore Sigma) in ethanol (0.02 mM), then 1 mL of 1 N HCl in a
saturated NaCl mixture and 1 mL of ethyl acetate were added. Tubes were vortexed, then rocked for
ten more minutes. The slurry was centrifuged at 1000 rpm for 10 min, then the upper organic phase was
carefully transferred to the clean reaction tube. Ethyl acetate extraction was repeated one more time, and
organic extracts were combined into one tube. Samples were completely dried under a nitrogen stream
at room temperature and incubated with 40 µL of metoxyamine in pyridine (20 mg/mL) at 80 ◦C for
1 h. Then tubes were cooled to the room temperature and 60 µL of bis-trimethylsilytrifluoroacetamide
(BSTFA)/1% trimethylchlorosilane (Millipore Sigma) was added following incubation at 70 ◦C for
45 min. Samples were transferred to the gas chromatography mass spectrometer (GCMS) vials.
2.3. Gas Chromatography-mass Spectrometry (GCMS) Analysis
GC-MS analysis was performed with Agilent 5977. A mass spectrometer coupled to a 7890 B
gas chromatograph fitted with a 7693 autosampler and a DB-5ms column (Agilent, Santa Clara, CA,
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USA). The GC-MS was operated as electron impact (EI)/single ion monitoring (SIM) mode. Target
ions and retention times can be found in Supplemental Materials. The temperature program was as
follows: 80 ◦C hold for 2 min, increase 15 ◦C/min up to 305 ◦C and hold for 3 min. Calibrations curves
with at least six points were obtained by plotting the metabolite/internal standard peak ratio versus
the metabolite concentrations in spiked plasma followed by linear regression analysis. The criteria
for acceptance was set as a correlation coefficient r2 > 0.99. Carryover was examined by extracting
spiked plasma samples with a high level of analytes followed by GC-MS runs of these samples and
blanks. The coefficients of inter- and intraday variation and accuracy of the spiked samples were
within acceptable limits (CV ≤ 20%).
Aconitate and Isocitrate Quantification
Since no commercially available stable isotope-labeled standards for aconitate and isocitrate were
found, tricarballylic acid (Supplemental material, Figure S2) was used as an internal standard for
these metabolites.
3. Results
Serum biochemistry was assessed including glucose, HbA1c, plasma creatinine, BUN, bilirubin,
albumin, triglycerides, total cholesterol, HDL-C, ALT, and AST, TNF-α and leptin. Table 1 summarizes
the mean standard blood clinical metrics obtained for NAFLD (n = 22) and matching controls (n = 67).
Some of the study participants had non fasting glucose levels, so Table 2 summarizes clinical metrics
for samples with plasma glucose ≤100 mg/dL. Non fasting glucose samples were excluded from Table 2
regardless of the HbA1c levels.
HbA1c—although the average value for the glycated hemoglobin (HbA1c) in the NAFLD group
didn’t exceed the 6.5% cut-off, this value indicates prediabetic conditions. Overall, 32% (7 out of 22) of
the NAFLD cohort had HbA1c ≥ 6.5%.
Albumin—decreased albumin levels are associated with cirrhosis, septal, intensive fibrosis, and
steatohepatitis. Analysis of the entire cohort including samples with the non fasting glucose revealed
that the average albumin level in affected individuals was decreased (3.8± 0.4 vs. 4.1± 0.2, respectively),
p < 0.05 (Table 1). After the exclusion of samples with non fasting glucose levels, no difference was
found in albumin values (Table 2).
Table 1. Demographics and standard plasma metrics expressed as average ±standard deviation.
ALP—alkaline phosphatase, ALT—alanine transferase, AST—aspartate transferase, BUN—blood
urea nitrogen, HDL-C—high-density lipoprotein cholesterol, TG—triglycerides, HSI—hepatic
steatosis index.
Control (n = 67) NAFLD (n = 22) p-Value
Age (years) 42.25 47.3
Male/Female 21/67 1/22
BMI (kg/m2) 29.7 ± 7.5 40 ± 7.5 <0.001
Albumin (g/dL) 4.01 ± 0.22 3.84 ± 0.43 0.02
Bilirubin (mg/dL) 0.77 ± 0.24 0.72 ± 0.40 0.50
ALP(U/L) 93.6 ± 16.8 95.4 ± 16.37 0.70
ALT (IU/L) 22.12 ± 6.5 30.19 ± 11.53 0.001
AST (IU/L) 21.4 ± 4.54 28.42 ± 11.12 <0.001
AST/ALT 1.00 ± 0.21 0.94 ± 0.23 0.3
BUN (mg/dL) 14.2 ± 3.8 15 ± 6.7 0.49
Creatinine (mg/dL) 0.82 ± 0.22 0.8 ± 0.2 0.70
Glucose (mg/dL) 90.7 ± 17.45 127.8 ± 77.1 0.005
HbA1c (%) 5.5 ± 0.77 6.5 ± 1.6 0.001
Total chol (mg/dL) 201 ± 47 192.3 ± 41.04 0.40
HDL-C (mg/dL) 47 ± 9.95 48 ± 13 0.39
TG (mg/dL) 171 ± 9.2 192.2 ± 123 0.89
TG/HDL-C 3.72 ± 2.22 4.21 ± 2.22 0.38
TNF-α (pg/mL) 1.86 ± 1.62 3.63 ± 2.8 <0.001
Leptin (ng/mL) 23 ± 18.09 63.0 ± 34 <0.001
HSI 39.19 ± 8.07 50.42 ± 14.9 <0.001
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Table 2. Demographics and standard plasma metrics expressed as average ±standard deviation only
for samples with glucose cut-off ≤100 mg/dL.
Control (n = 57) NAFLD (n = 7) p Value
Age (years) 42.1 46
Male/Female 16/41 1/8
BMI (kg/m2) 29.5 ± 7.9 32.4 ± 10.5 0.3
Albumin (g/dL) 3.98 ± 0.21 3.97 ± 0.32 0.92
Bilirubin (mg/dL) 0.77 ± 0.24 0.62 ± 0.16 0.07
ALP(U/L) 94.8 ± 16.1 95.8 ± 21.4 0.8
ALT (IU/L) 21.7 ± 5.4 29.6 ± 13.3 0.002
AST (IU/L) 21.1 ± 4.5 30.0 ± 13.0 <0.001
BUN (mg/dL) 14.03 ± 3.66 15.0 ± 5.5 0.50
Creatinine (mg/dL) 0.79 ± 0.18 0.75 ± 0.26 0.55
Glucose (mg/dL) 85.35 ± 9.38 88.88 ± 10.7 0.30
HbA1c (%) 5.45 ± 0.54 5.9 ± 0.4 0.44
Total chol (mg/dL) 199.3 ± 48 179.6 ± 26.2 0.23
HDL-C (mg/dL) 47 ± 10 47 ± 12 0.76
TG (mg/dL) 159 ± 84 150 ± 58.1 0.90
TG/HDL-C 3.4 ± 1.7 1.9 ± 0.84 0.84
TNF-α (pg/mL) 1.8 ± 1.1 3.57 ± 3.01 0.01
Leptin (ng/mL) 24.18 ± 18.6 61.68 ± 32.2 <0.001
HSI 38.9 ± 8.35 41.27 ± 11.36 0.45
Transaminases—alanine aminotransferase (ALT) activity, a marker of the hepatic damage,
was significantly elevated (p < 0.05) regardless of the fasting status. The difference in aspartate
aminotransferase (AST) activity between the normal and affected cohort became more evident in the
group with glucose <100 mg/dL cut-off. The AST/ALT ratio, which is often used as an independent
predictive factor for advanced hepatic fibrosis [13], was not significantly different between the two
groups (Table 1). It is important to note that fifty percent of the NAFLD population can present with
normal AST and ALT levels [14,15].
Bilirubin—although bilirubin levels were reported to be inversely associated with NAFLD [16],
we didn’t observe a statistically significant difference in our cohorts.
Plasma creatinine, a common marker in cirrhosis and chronic kidney disease, also was not
significantly different.
Increased triglycerides (TG) and decreased high-density lipoprotein cholesterol (HDL-C) are
associated with metabolic syndrome [17]. It is interesting to note that the NAFLD cohort had elevated
triglycerides but no difference in HDL-C level. Despite this, the triglycerides/high-density lipoprotein
cholesterol ratio, reported in association with insulin resistance, was elevated in the NAFLD group.
Body mass index (BMI) is associated with fatty liver risk [18]. In this regard, we found a statistically
significant BMI increase in the NAFLD cohort (Table 1), which became less apparent when only samples
with glucose cut-off <100 mg/dL were included for the analysis (Table 2).
Hepatic steatosis index (HSI) was calculated using demographic and standard plasma metrics
(Figure S4, Supplemental materials) [19]. In accordance to a study by Lee et al., HSI correlates
significantly with fatty liver grade with a screening cut-off of >36.0 and likely reflects the presence of
nonalcoholic steatohepatitis [19].
The Krebs cycle has a central role in liver metabolism, connecting hepatic fatty acid and
glucose-related pathways. Abnormal cellular [20] and circulating [21] Krebs cycle intermediates are
closely associated with mitochondrial dysfunction as was demonstrated in numerous studies [22–25].
Given the decreased activity in respiratory chain complexes in NAFLD [4], perturbations in cellular
concentrations of Krebs cycle intermediates are expected.
Seven circulating Krebs cycle intermediates were analyzed including citrate, isocitrate, aconitate,
α-ketoglutarate, succinate, fumarate, and malate. Oxaloacetate is not chemically stable and hence was
omitted from the analyses. Succinyl-CoA is a cellular metabolite and consequently is not abundant
in human plasma. Statistically significant increases were detected in circulating levels of citrate and
isocitrate regardless of the plasma glucose levels (Figure 1).
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Figure 1. Plasma Krebs cycle intermediates levels by GCMS. Nonalcoholic fatty liver disease (NAFLD)
(n = 22) and controls (n = 67). Statistical analysis performed by Prism 8 (GraphPad). * p < 0.05.
Diagnostic performance of isocitrate and citrate in NAFLD patients was further analyzed by
establishing the receiver operating curve (ROC) and analyzing the area under the curve (AUC)
(Figure 2). The accuracy of both isocitrate and citrate to discriminate NAFLD from the control cohort
showed similar areas under the curve (AUROC) of 0.74 and 0.75, respectively (Table 3).
Table 3. Evaluation of isocitrate and citrate as mitochondrial dysfunction markers in NAFLD.
AUC—area under the curve.
Marker AUC p-Value Error
Citrate 0.749 p < 0.05 0.097
Isocitrate 0.750 p < 0.05 0.102
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Correlations between plasma Krebs cycle intermediates and standard clinical plasma metrics were
explored by Pearson’s correlation coefficient. The most significant correlations were obtained in the
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NAFLD cohort for α-ketoglutarate to the BUN (r = −0.7969, p < 0.05). In the control group, plasma
succinate was positively correlated with albumin (r = 0.353, p = 0.01), malate negatively correlated to
AST (r = −0.332, p = 0.02), α-ketoglutarate was negatively correlated to glucose (r = −0.562, p < 0.001),
aconitate was negatively correlated to bilirubin (r = −0.281, p = 0.04), and fumarate was negatively
correlated to AST and ALT (r = −0.315, p = 0.02; r = −0.298, p = 0.03). When the entire population under
the study was analyzed, the correlation analysis revealed that isocitrate was strongly correlated with
age and bilirubin levels (r = 0.29, p = 0.005; r = −0.02, p = 0.04, respectively) and inflammatory markers
(TNF-α and leptin), while citrate was correlated with age (r = 0.345, p < 0.001), AST activity (r = 0.249,
p = 0.02), glucose levels (r = 0.284, p = 0.008), HSI, TNF-α, and leptin (Figure 3). Koliaki et al. [26]
demonstrated that the metabolic flexibility of hepatic mitochondria in the early stages of NAFLD is
lost at the NASH stage. We utilized calculated HSI values as a proxy of NAFLD staging and found a
positive correlation to citrate levels (Figure 3).
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4. Discussion
Nonalcoholic liver disease (NAFLD) is the most common form of chronic liver disease. There is
emerging evidence that mitochondrial dysfunction contributes to NAFLD pathogenesis. However,
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there are no noninvasive markers that assess mitochondrial involvement in NAFLD. In this study,
we analyzed plasma levels of seven Krebs cycle intermediates and investigated their correlation with
the standard indices and their potential role as biomarkers of mitochondrial dysfunction in NAFLD.
As expected in NAFLD, transaminase activities were elevated (Table 2) and albumin levels
were decreased. Interestingly, we did not find a significant difference in plasma creatinine levels,
suggesting that the NAFLD cohort at the time of the study did not have significant renal dysfunction.
No statistical difference was also found in BUN, a suggestive cardiovascular disease (CVD) risk factor
in NAFLD [27]. Sixty-three percent (12/22) of NAFLD patients had BMI > 30 kg/m2. About thirty-two
percent of the NAFLD cohort demonstrated HbA1c levels in diabetic range (>6.5%) and the same
percentage of the cohort had high triglyceride levels (>200 mg/dL), indicating the presence of metabolic
syndrome. An increase in inflammatory markers TNF-α and leptin are associated with NAFLD and
NASH [8,28,29]. Uygun et al. [30] and Chitturi et al. [31] demonstrated in their studies that an increase
in serum leptin in patients with steatohepatitis has no relation to BMI and thus can’t be justified by
type 2 diabetes, sex, or obesity. In another study, Serin et al. [32] showed that elevated serum leptin is
characteristic of the steatotic patients with normal transaminase levels.
Krebs cycle has a central role in liver metabolism, connecting hepatic fatty acids and glucose-related
pathways. Abnormal cellular [20] and circulating [21] Krebs cycle intermediates are closely associated
with mitochondrial dysfunction, as was demonstrated in a number of studies [22–25]. Given the
decreased activity in respiratory chain complexes in NAFLD [4], perturbations in cellular concentrations
of Krebs cycle intermediates are expected. The data obtained for plasma Krebs cycle intermediates
suggest pathophysiological insights that link mitochondrial dysfunction with NAFLD. In the present
studies, NAFLD patients had higher plasma citrate levels than healthy control subjects. This finding is
consistent with the van der Wier et al. study that reported elevated plasma citrate levels in NAFLD
patients [33]. The study also suggested that fatty acids accumulation lead to the plasma citrate elevation
in NAFLD. The increase in plasma citrate can also be associated with upregulated de novo lipogenesis
in NAFLD [34,35]. Citrate serves a carbon precursor in fatty acids’ de novo biosynthesis and although
less than 10% of hepatic citrate originates from plasma citrate [36], overall about 26.1% of accumulated
liver triacylglycerols originate from the de novo lipogenesis [35].
We also observed an increase in circulating isocitrate levels (p < 0.05). Isocitrate is converted
to α-ketoglutarate through oxidative decarboxylation and catalyzed by isocitrate dehydrogenase
(IDH). There are three different human IDH isoforms described: NAD+-dependent IDH3 and
NADP+-dependent forms IDH1/IDH2. IDH1 is highly expressed in the liver and IDH2 plays a
key role in Krebs cycle regulation in multiple tissues. IDH3 is located in the mitochondria and catalyzes
the rate-limiting step of irreversible conversion of isocitrate to α-ketoglutarate. Although we did
not observe abnormalities in plasma α-ketoglutarate, the increase in isocitrate levels is consistent
with the observation that IDH2 expression in primary hepatocytes is downregulated under palmitate
stimulation and lipid accumulation [37].
For the correlation analyses, we selected all samples regardless of glucose levels (Table 1).
The most prominent finding in the NAFLD cohort was a negative correlation between plasma
α-ketoglutarate levels and BUN (r = −0.7969, p < 0.05). This may be related to cataplerosis (loss
of Krebs cycle intermediates) of α-ketoglutarate due to hyperammonemia that has been reported
in preclinical models of NAFLD [38]. This is consistent with our previous report that Krebs cycle
intermediate levels, including α-ketoglutarate, were significantly lower in C2C12 myotube cells during
hyperammonemia [39]. Batshaw et al. also reported a similar linear inverse correlation between
plasma ammonia and α-ketoglutarate levels [40] in infants with ornithine transcarbamylase deficiency.
The correlation analysis of the entire population under the study revealed that citrate and isocitrate
were correlated with age (range 23–67 years, Figure 3). Citrate was also positively correlated with
glucose (r = 0.2839, p < 0.05) and HbA1c (r = 0.3844, p < 0.001). This is similar to a previous report
by Shigiyama et al. that showed citrate levels are elevated in NAFLD patients with a high hepatic
insulin sensitivity group [41]. The same study also reported an increase in succinate and aconitate, but
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we did not find a statistically significant association of these metabolites with glucose in our subjects.
However, we noted that aconitate had a strong negative correlation to HDL-C in the control group (r =
−0.26, p = 0.03, Supplemental data). We also noted a negative correlation of isocitrate to bilirubin that
can be explained by bilirubin being a potent inhibitor of isocitrate dehydrogenase [42,43].
To evaluate isocitrate and citrate performance as mitochondrial dysfunction markers, receiver
operating curves (ROCs) were constructed and areas under the curve were calculated. The AUC
values indicate that isocitrate and citrate (AUC = 0.74 and AUC = 0.75) have a moderate biomarker
performance. However, larger cohorts of control subjects and NAFLD patients can potentially improve
these characteristics.
While serum liver disease markers for NAFLD have been established, the secondary noninvasive
mitochondrial dysfunction markers in NAFLD are still to be investigated. Through the plasma Krebs
cycle intermediates analysis, we present evidence of mitochondrial dysfunction involvement in the
NAFLD phenotype. Our findings suggest that plasma isocitrate and citrate can discriminate between
normal and NAFLD cohorts and can be utilized as noninvasive mitochondrial dysfunction biomarkers
in NAFLD. Future mechanistic studies in NAFLD disease models and analysis of plasma Krebs cycle
intermediates with large populations at different NAFLD stages are warranted.
Study limitations—since no liver biopsy has been performed, the assumption that NAFLD
cohort has mitochondrial dysfunction is based on the multiple studies that demonstrated evidence of
molecular, biochemical, and biophysical mitochondrial abnormalities in the NAFLD phenotype. It is
important to note that control subjects under the study were of both genders, but the NAFLD cohort
included only one male. Thus, our findings need to be validated with a more gender-inclusive group of
NAFLD patients. In addition, results of this study need to be validated with large cohorts and against
different stages of NAFLD, including nonalcoholic steatohepatitis (NASH) and advanced fibrosis.
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